2012 Drug Carriers in Medicine and Biology Gordon Research Conference

描述（由申请人提供）：我们为将于2012年8月12日至17日在新罕布什尔州沃特维尔谷举行的戈登医学和生物学药物载体研究会议寻求部分支持。会议将集中讨论代表药物和成像探针递送和靶向载体的关键研究领域的主题，包括新载体和材料的设计，血管药物递送，靶向癌症，细胞内递送和运输，疫苗递送，局部递送和屏障，药物递送到器官系统，递送的生物控制及其效果和药物载体的转化方面。因此，会议的副主题将是“转化药物载体：从设计和理解作用机制到临床应用”。演讲者和讨论领导者是各自领域公认的领导者，是在与代表给药领域广度的科学家协商后选出的。特别注意发言者和其他与会者的多样性。这个暂定方案在性别、年龄、职业阶段、地点和其他多样性参数方面反映了这一点。特别是，我们计划在每个会议中至少有一个简短的演讲，由有前途的研究人员在早期的职业生涯阶段（到早期副教授和年轻的工业研究人员）。我们设计了一个非常高质量的节目，其中大约50%的演讲者是女性。我们将通过登记和资助代表性不足的群体成员（特别是学员）参加会议，进一步促进多样性。这项建议寻求专门为此目标提供部分校外资金。培训方面以三次海报会议的形式纳入该计划，并从学员的海报展示中选择简短的演讲。该GRC传统的非正式、学院式的氛围中，约有100名参与者在他们的专业、年龄、隶属关系和职业阶段进行互动，这有利于本次会议的研究和培训任务。GRC的具体目标是：1)提供一个讨论最新药物载体研究的论坛。2)将从事药物传递设计（即生物工程、生物技术、成像和制药科学）的科学家、专注于该领域生物医学方面（即细胞和分子生物学、免疫学和医学方面）的科学家和行业代表聚集在一起，整合所有翻译。3)通过识别知识差距和改进概念模型，确定未来几年的优先研究主题。4)继续为学员和高级研究人员之间的互动提供高质量和无障碍的场所。

DESCRIPTION (provided by applicant): We seek partial support for the Gordon Research Conference on Drug Carriers in Medicine and Biology, to be held at Waterville Valley, NH, August 12-17 in 2012. The conference will focus on topics that represent key research areas in carriers for drug and imaging probe delivery and targeting including design of novel carriers and materials, vascular drug delivery, targeting cancer, intracellular delivery and trafficking, vaccin delivery, local delivery and barriers, drug delivery to organ systems, biological control of the delivery and its effects and translational aspects of drug carriers. The sub-theme of the conference will thus be "Translational drug carriers: from design and understanding mechanism of action to clinical use". Speakers and discussion leaders are recognized leaders in their fields and were chosen in consultation with scientists who represent the breadth of the field of drug delivery. Special attention has been given to diversity of the speakers and other participants. The tentative program reflects this in terms of gender, age, career stage, location and other diversity parameters. In particular, we projected at least one short-talk in each session given by promising investigators at early career stage (up to early Associate Professors and young industrial researchers). We have devised an extremely high-quality program that features about 50% female speakers. We will boost diversity further through registration and via financial support for the attendance of members of under- represented groups (especially trainees). This proposal seeks partial extramural funding specifically for this goal. Training aspects are incorporated into the program in the form of three poster sessions and short talks selected from the poster presentations given by trainees. Traditional informal, collegial atmosphere of this GRC, in which about a hundred participants interact across their specialties, ages, affiliations and career stages facilitates both research and training mission of this meeting. The specific objectives of the GRC are: 1) To provide a forum for discussion of the latest drug carrier research. 2) To bring together scientists working in the drug delivery design (i.e., bioengineering, biotechnology, imaging and pharmaceutical sciences), those focused in the biomedical aspects of the field (i.e., cell and molecular biology, immunological and medical aspects) and representatives of industry, to integrate across all translational. 3) To identify priority research themes for the coming years by identifying gaps in knowledge and improving conceptual models. 4) To continue to provide a high quality and accessible arena for interaction between trainees and senior researchers. PUBLIC HEALTH RELEVANCE: Targeted delivery of drugs and imaging agents to the sites of pathology where their activity is needed is a Holy Grail of modern biomedicine. It will provide safer and more effective means for diagnosis, prophylaxis and treatment of prevalent disease conditions including cancer, infectious diseases, cardiovascular, pulmonary and neurological disorders, among a plethora of human maladies. Translation of these drug carriers into the biomedical domain, industrial development and clinical use will benefit a plethora of diagnostic and pharmacotherapy approaches, especially those employing novel classes of molecular imaging probes and biologicals including siRNA, enzyme therapies and biological modulators. These new means for targeted molecular interventions and imaging hold promise to provide a major impact on human health and, in fact, revolutionize modern biomedicine.